Dr. Reddy Q3 2024 EPS Rs82.68 Up From Rs74.95 YoY; Revenue Rs72.148M Up From Rs67.700M YoY
Portfolio Pulse from Benzinga Newsdesk
Dr. Reddy's Laboratories reported a year-over-year increase in Q3 2024 earnings per share (EPS) to Rs82.68 from Rs74.95, and a revenue increase to Rs72.148 million from Rs67.700 million.
January 31, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dr. Reddy's Laboratories (RDY) reported an increase in Q3 2024 EPS and revenue, indicating a positive performance year-over-year.
The reported increase in both EPS and revenue for Dr. Reddy's Laboratories suggests a strong financial performance, which is typically viewed positively by investors and can lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100